| ●Editorial | Kageyama S | 4 |
| ●10th annual meeting of the Japan Society of Clinical Pharmacological Studies | ||
| Organized by: Clinical Research Trial Center, Ehime University Hospital | President: Nomoto M | 7-161 |
| Genetic polymorphisms of drug transporters; Effects on intestinal drug absorption and drug interactions | Ieiri I | 9-22 |
| Effect to establish PGx-based clinical trials | Azuma J | 23-40 |
| Pharmacogenomics in drug development: Significance and issues | Yasuda S | 41-53 |
| Implications and limitations of pharmacogenomic information to clinical practice | Echizen H | 54-63 |
| Public acceptance of pharmacogenetics | Tsutani K | 64-80 |
| Ethical committee on genetic research | Kobayashi S | 81-8 |
| Perspective in international global clinical trials | Mizuno Y | 89-100 |
| Promotion of clinical trial with considering regional diversity | Iwasaki K | 101-15 |
| Traning course of investigators and social medicial system on international clinical trials | Nomoto M | 116-26 |
| Guidance on microdose clinical trials and perspective of early stage exploratory clinical trials | Ikeda T | 127-39 |
| Practical aspects of early clinical trials | Kumagai Y | 140-50 |
| Protecting human subjects in early phase clinical trials | Kurihara C | 151-61 |
| ●The 27th Aso-Kujyu Conference on Clinical Pharmacology To create the evidence for drug therapy in the globalization era | ||
| Chairman: Ohashi K, Nomoto M, Higuchi S, Sasaguri T, Nakano S, Hasegawa J, Yamada K | 163-278 | |
| Opening remarks | Ohashi K | 166 |
| Comment from clinical investigators | Noda K | 167-72 |
| Comment from Clinical Research Coordinator | Kuranari M | 173-8 |
| The present situation of IRB in Japan | Sasaguri T | 179-87 |
| PMDA’s perspective | Sato J | 188-91 |
| Double entry of human subjects in clinical trials | Iijima H | 192-7 |
| The New 5-Year Clinical Trial Activation Plan and the promotion of global clinical trials | Sato T | 198-215 |
| Education for future staff to develop and foster drugs in Japan | Nakano S | 216-20 |
| Desired attitude of academia toward clinical research | Kumagai Y | 221-8 |
| The six years pharmacy education system advances the Evidence Based Pharmaceutical Care | Higuchi S | 229-35 |
| Glocal Network and project management in clinical trials | Morimoto T | 236-42 |
| Discussion | 243-4 | |
| Natural supplements consultation in Ehime University Hospital | Nagai M | 245-50 |
| The interaction between drugs and fruits | Kotegawa T | 251-7 |
| The evidence of benefit for food and diatary supplements | Hasegawa J | 258-66 |
| Clinical evaluation of food for specified health use (FOSHU) | Hirayama Y | 267-76 |
| Closing remarks | Nomoto M, Higuchi S | 277 |
| ●Review | ||
| Gender and ethnic variability of the clinical pharmacokinetics of transporter substrates; HMG-CoA reductase inhibitors and Angiotensin II receptor antagonists | Tomita Y, Maeda K, Sugiyama Y | 279-96 |
| ●Manual for diagnosis of Adverse Drug Event | Shimizu N | 297-362 |
| ●Forum | ||
| Problems in the marketing prices of EpiPen Injection | Kamada I, Nishima S | 363-6 |
| ●Instructions for authors [Japanese] & [English] | 367-72 | |
| ●Editor's note | Mitsuishi T | 373 |